US.ABBV · AbbVie

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.0981658400575878,
        "turnoverUsdM": 1360.675532646,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.ABBV",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 253.8414,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.2,
      "take_profit_price": 278.208,
      "target_multiplier": 1.9,
      "technical_strength": 1.65,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.1963316801151755,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 72.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 59.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 13
  },
  "market": {
    "ma20": 253.294,
    "ma50": 247.9872,
    "close": 264.96,
    "prevClose": 261.83,
    "avgVolume20": 5422270,
    "volumeRatio": 0.95,
    "changePercent": 1.2
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 13,
    "details": {
      "ret_5d": 0.06213412722945044,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 13,
      "vcp_bonus": 0,
      "vol_ratio": 0.9553788195897865,
      "ret_points": 12,
      "vol_points": 0,
      "range_ratio": 1.1356091155063528,
      "volat_points": 0,
      "day_range_pct": 0.025437765150881753,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 72.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 46,
        "contribution": 2.3
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 9.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 61.33,
        "contribution": 9.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 20.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67.67,
        "contribution": 20.3
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 59.8,
    "details": [
      "基本面分析總分: 2.3/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 9.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 20.3/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.3,
      "資金流": 12.4,
      "市場環境": 9.2,
      "情緒分析": 6,
      "技術信號": 20.3,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 1360.675532646,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.ABBV",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.01
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 709.1885013500001,
                "ma50": 713.4416018399997,
                "name": "QQQ",
                "close": 713.44,
                "points": 1
              },
              "spy": {
                "ma20": 762.32700215,
                "ma50": 751.7496043999998,
                "name": "SPY",
                "close": 765.71997,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.0981658400575878,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141278176,
                "url": "https://finnhub.io/api/news?id=60c1d685b6f9f61242d6bb6b2e8b7cb7a7bd12cfd211b1e9ef20c29498fd2d3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) unveiled new clinical data at the 2026 World Conference on Lung Cancer that covers several lung cancer programs across its pipeline. Key updates included efficacy and safety readouts for investigational therapies ABBV-1480, telisotuzumab adizutecan, and ABBV-706 in non small cell and small cell lung cancer. The company outlined an expanded set of ongoing lung cancer trials that it stated could reshape its future oncology portfolio and longer term growth profile. For...",
                "category": "company",
                "datetime": 1787332273,
                "headline": "AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026"
              },
              {
                "id": 141272430,
                "url": "https://finnhub.io/api/news?id=c1c8f433c9e3ecc1be8382ae26b6e9f63d8875fd36d4f809ebf51ef75033bf82",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer",
                "category": "company",
                "datetime": 1787298429,
                "headline": "AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer"
              },
              {
                "id": 141216587,
                "url": "https://finnhub.io/api/news?id=e0bfe2d8f1befab153ba143c71be4362c346fc315cdcd21e2c0c3bf657df1d57",
                "image": "",
                "source": "Fintel",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1786717602,
                "headline": "Wolfe Research Upgrades AbbVie (ABBV)"
              },
              {
                "id": 141212149,
                "url": "https://finnhub.io/api/news?id=06ce5ec61bf64aaa7c2229ee32f5c18ed46a26b1f616e9dbdf69a8cc211b50fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]",
                "category": "company",
                "datetime": 1786664315,
                "headline": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?"
              },
              {
                "id": 141210872,
                "url": "https://finnhub.io/api/news?id=0dbf6b24d123f0a154351a53eec26a89c1aa6fe99f4dd3171433292f42b33bbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D […]",
                "category": "company",
                "datetime": 1786656786,
                "headline": "Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200618,
                "url": "https://finnhub.io/api/news?id=13f1298ebc4c518c0dd79feda3636de8fb9afa9966b4932b224c23998ef49532",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...",
                "category": "company",
                "datetime": 1786486514,
                "headline": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment"
              }
            ],
            "raw_source": [
              {
                "id": 141300693,
                "url": "https://finnhub.io/api/news?id=b2d3954f42ad4308cb6ececb4c1f27e3744121249232ae5fd9158ac623138f63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445033385/image_1445033385.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Nvidia earnings, core PCE inflation and Warsh’s Jackson Hole debut could move markets.",
                "category": "company",
                "datetime": 1787469186,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141278176,
                "url": "https://finnhub.io/api/news?id=60c1d685b6f9f61242d6bb6b2e8b7cb7a7bd12cfd211b1e9ef20c29498fd2d3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) unveiled new clinical data at the 2026 World Conference on Lung Cancer that covers several lung cancer programs across its pipeline. Key updates included efficacy and safety readouts for investigational therapies ABBV-1480, telisotuzumab adizutecan, and ABBV-706 in non small cell and small cell lung cancer. The company outlined an expanded set of ongoing lung cancer trials that it stated could reshape its future oncology portfolio and longer term growth profile. For...",
                "category": "company",
                "datetime": 1787332273,
                "headline": "AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026"
              },
              {
                "id": 141278177,
                "url": "https://finnhub.io/api/news?id=d3e097a5d8c15fd8c5176dca5c1ad75b2bd1ca513727d8d1be6ca306e501211f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker ident",
                "category": "company",
                "datetime": 1787316300,
                "headline": "AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline"
              },
              {
                "id": 141278181,
                "url": "https://finnhub.io/api/news?id=5313d91c3b843c6f3a057b8170dbd154d190a706415bf1a358d2947c51990ca0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
                "category": "company",
                "datetime": 1787315987,
                "headline": "3 Unpopular Stocks That Deserve Some Love"
              },
              {
                "id": 141272430,
                "url": "https://finnhub.io/api/news?id=c1c8f433c9e3ecc1be8382ae26b6e9f63d8875fd36d4f809ebf51ef75033bf82",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer",
                "category": "company",
                "datetime": 1787298429,
                "headline": "AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer"
              },
              {
                "id": 141278041,
                "url": "https://finnhub.io/api/news?id=b6b8b6bb83ce7842471b2d3ff17fd226a74f65641d1cab1c940ba182d5fc7a99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.",
                "category": "company",
                "datetime": 1787250436,
                "headline": "Merck Stock Ran On A Checklist Published In Advance"
              },
              {
                "id": 141278042,
                "url": "https://finnhub.io/api/news?id=a185f67366da2df6e04ff21b866c03090a3bb454dfce33b84acf2978013b48e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.",
                "category": "company",
                "datetime": 1787248494,
                "headline": "Pfizer Stock Is A Race Between New Drugs And Old Patents"
              },
              {
                "id": 141278178,
                "url": "https://finnhub.io/api/news?id=825fce49981a44b34b1fcec43c28562d1e561a59a0a7eb4ae5530e27f611253d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 pushes well beyond what Wall Street consensus currently projects, and the catalysts behind each target may surprise you.",
                "category": "company",
                "datetime": 1787247035,
                "headline": "Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead"
              },
              {
                "id": 141278184,
                "url": "https://finnhub.io/api/news?id=3ea1d143456f4c7d9dc7cd996cce3a54cc68abe50ff8abf5c998e7b1c4fae3f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.",
                "category": "company",
                "datetime": 1787244840,
                "headline": "GKOS Stock Surges 67% Year to Date: What's Driving the Rally?"
              },
              {
                "id": 141278185,
                "url": "https://finnhub.io/api/news?id=b6f5547aae60787470f795a553206b912e475489277993b14623fbbb126e01ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.",
                "category": "company",
                "datetime": 1787240880,
                "headline": "Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?"
              },
              {
                "id": 141278139,
                "url": "https://finnhub.io/api/news?id=fcd332a3e0e30fe8a0f7d63cb0a926be225e4bb853171cc00071bc6cf71d34d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.",
                "category": "company",
                "datetime": 1787240431,
                "headline": "Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO"
              },
              {
                "id": 141265376,
                "url": "https://finnhub.io/api/news?id=a1b2cbf52cdcac69f367a4c5d8d777f76a215fe0fbbd1c88e4f1ed7fe19ee1df",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Piper Sandler  analyst David Amsellem   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.",
                "category": "company",
                "datetime": 1787228114,
                "headline": "Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303"
              },
              {
                "id": 141263972,
                "url": "https://finnhub.io/api/news?id=c214f7edde73e38268c28f3292e33e368242c402dff0bce82285ce82ed18e751",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.",
                "category": "company",
                "datetime": 1787223588,
                "headline": "Why Is Merck Stock Still Undervalued After An 80% Surge?"
              },
              {
                "id": 141265019,
                "url": "https://finnhub.io/api/news?id=3efe1267e5f6f11310f69d408807179b90b236964e8bbc86180a9ae298656234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.",
                "category": "company",
                "datetime": 1787173696,
                "headline": "Johnson & Johnson Stock Runs On A Calendar The Market Does Not Set"
              },
              {
                "id": 141278141,
                "url": "https://finnhub.io/api/news?id=f9a21b5be4efd6c3499dc4de20ff1853c616d3d46fa5e2c4daf0a6b0846d3792",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.",
                "category": "company",
                "datetime": 1787172052,
                "headline": "Is AbbVie Stock About To Break Out Again?"
              },
              {
                "id": 141278190,
                "url": "https://finnhub.io/api/news?id=bd31c4f774a8001880ac335a7929b8583da52983043d51e50f7a2be5384202a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1787160756,
                "headline": "Real Parkinson’s Disease Hope from Jupiter Neurosciences"
              },
              {
                "id": 141254920,
                "url": "https://finnhub.io/api/news?id=e89c64709ddd6a7995aae1754791a3f6d88481af9be88c0efb732c183203d1e2",
                "image": "",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1787148432,
                "headline": "Novo Nordisk: The Best Value In Pharma"
              },
              {
                "id": 141278191,
                "url": "https://finnhub.io/api/news?id=0e45fb5918e6aef86d7c7007e1515e398894910359d485907644078f3193217c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.",
                "category": "company",
                "datetime": 1787141400,
                "headline": "Billionaire Ken Griffin Increased His Position in This Dividend King by 547%"
              },
              {
                "id": 141278192,
                "url": "https://finnhub.io/api/news?id=c16a4fc0b4883ced1e09a9b7c881e88177284270c9e703188f98c2fc2d2d929d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.",
                "category": "company",
                "datetime": 1787065823,
                "headline": "Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore"
              },
              {
                "id": 141247734,
                "url": "https://finnhub.io/api/news?id=a607edaa23bb540143fdfe73de9dde5d38de54822e9469632d272690e461761a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787060120,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141278179,
                "url": "https://finnhub.io/api/news?id=79931f6c8ec57b8d7f52a4111b348cb66324ff1c625802c0b5acc4d064f003a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology will receive the 2026 AbbVie Immunology Scholarship, as the program marks its 10th year.",
                "category": "company",
                "datetime": 1787058000,
                "headline": "AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141238857,
                "url": "https://finnhub.io/api/news?id=292ccba92e495cfc2bc773b240ec1429bff79de77dddc692c061eca0a3ebad65",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.",
                "category": "company",
                "datetime": 1786957469,
                "headline": "Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300"
              },
              {
                "id": 141216587,
                "url": "https://finnhub.io/api/news?id=e0bfe2d8f1befab153ba143c71be4362c346fc315cdcd21e2c0c3bf657df1d57",
                "image": "",
                "source": "Fintel",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1786717602,
                "headline": "Wolfe Research Upgrades AbbVie (ABBV)"
              },
              {
                "id": 141212149,
                "url": "https://finnhub.io/api/news?id=06ce5ec61bf64aaa7c2229ee32f5c18ed46a26b1f616e9dbdf69a8cc211b50fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]",
                "category": "company",
                "datetime": 1786664315,
                "headline": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?"
              },
              {
                "id": 141212141,
                "url": "https://finnhub.io/api/news?id=b37de892ed668dadc063cca94c87fdf98a4674d68db4572b055b93442e76bb04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]",
                "category": "company",
                "datetime": 1786662446,
                "headline": "Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?"
              },
              {
                "id": 141210872,
                "url": "https://finnhub.io/api/news?id=0dbf6b24d123f0a154351a53eec26a89c1aa6fe99f4dd3171433292f42b33bbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D […]",
                "category": "company",
                "datetime": 1786656786,
                "headline": "Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141206518,
                "url": "https://finnhub.io/api/news?id=9069d19d991acf04b9fca1c8a243ae50a474fe8d50a62762c1f60f1f800987d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.",
                "category": "company",
                "datetime": 1786629121,
                "headline": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation"
              },
              {
                "id": 141209899,
                "url": "https://finnhub.io/api/news?id=d1a76c860af5738244eaf199d5b7aadc2e317507eca44c358c8ce07d3a785a86",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Wolfe Research  analyst Alexandria Hammond   upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.",
                "category": "company",
                "datetime": 1786626886,
                "headline": "Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target"
              },
              {
                "id": 141204884,
                "url": "https://finnhub.io/api/news?id=2f7edaf5d4d41b70d1c840109cb90b6618fd34f237bd841243f92642f438c4d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.",
                "category": "company",
                "datetime": 1786622027,
                "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More"
              },
              {
                "id": 141203838,
                "url": "https://finnhub.io/api/news?id=b33f48fc75f1b9ffcfdf982f5269f978b42b2ad1137e5f452919966d0bda6944",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249791973/image_2249791973.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Key Contributors include Palo Alto Networks, ASML Holding, and Taiwan Semiconductor. Read more here.",
                "category": "company",
                "datetime": 1786596000,
                "headline": "American Century Focused Global Growth Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141200513,
                "url": "https://finnhub.io/api/news?id=c73a8f0475758d31cd448380b74cbbb1c57e712f593a1a9679b90a05f53a54ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.",
                "category": "company",
                "datetime": 1786559422,
                "headline": "Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield"
              },
              {
                "id": 141200500,
                "url": "https://finnhub.io/api/news?id=ff75988727fcba1e5d818840746487c01f069e154db33e9b2aabc87f756101ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Four dividend giants from energy and pharma quietly generate the bulk of HDV's income, but their balance sheets and payout coverage look nothing alike. Before trusting that 3% yield, it pays to know which checks are ironclad and which carry a hidden catch.",
                "category": "company",
                "datetime": 1786551148,
                "headline": "The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is"
              },
              {
                "id": 141189365,
                "url": "https://finnhub.io/api/news?id=3af242c14af2e122129a8e9419b3189b5d2cbedcadc8635aa37d3a59154b3ac7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.",
                "category": "company",
                "datetime": 1786489797,
                "headline": "JNJ Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 141200618,
                "url": "https://finnhub.io/api/news?id=13f1298ebc4c518c0dd79feda3636de8fb9afa9966b4932b224c23998ef49532",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...",
                "category": "company",
                "datetime": 1786486514,
                "headline": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment"
              },
              {
                "id": 141189366,
                "url": "https://finnhub.io/api/news?id=875b935af433bfa3030edf6eff7cc254c4ffb82289f22197cb75fd2f1a2404bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.",
                "category": "company",
                "datetime": 1786484330,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off"
              },
              {
                "id": 141200620,
                "url": "https://finnhub.io/api/news?id=51347be87f89806a9331772ef84322ca498b19554d6d04c6e9f0864dd5d05b81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie’s share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year total...",
                "category": "company",
                "datetime": 1786482692,
                "headline": "AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?"
              },
              {
                "id": 141200621,
                "url": "https://finnhub.io/api/news?id=a08e7c7fa18be82606ea2feeb7ddeeada1626fe5e95e301c926252196ccedab8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.",
                "category": "company",
                "datetime": 1786481221,
                "headline": "AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141189360,
                "url": "https://finnhub.io/api/news?id=f5932c9df04bd778e326a6ee5cebd833aba4d5b273c91902ce74816c1abdff6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Both of these stocks pay more than double the S&P 500 average of 1.1%.",
                "category": "company",
                "datetime": 1786468523,
                "headline": "Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?"
              },
              {
                "id": 141200526,
                "url": "https://finnhub.io/api/news?id=bb45ea9039c763833121ecfb68e434d16b3cf6fb8431480eca4c3f9568d605b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.",
                "category": "company",
                "datetime": 1786467240,
                "headline": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?"
              },
              {
                "id": 141200624,
                "url": "https://finnhub.io/api/news?id=36b93b198d828126826d33226504fa9d1104c2738ade7d2bb2d617000b8f436b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.",
                "category": "company",
                "datetime": 1786460414,
                "headline": "Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run"
              },
              {
                "id": 141188929,
                "url": "https://finnhub.io/api/news?id=054e1ed058edf4927c19ffb2c9283479609da027175841f5bcaabb478837c7e6",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "BNP Paribas  analyst Navann Ty   maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.",
                "category": "company",
                "datetime": 1786456534,
                "headline": "BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247"
              },
              {
                "id": 141200625,
                "url": "https://finnhub.io/api/news?id=a4f64e1367b0eeac052bdbb21dc48e23a1ab4e3feac3e16bc11a981beb1d3c2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges® (APP), its customer portfolio loyalty program, designed to better support the way today's aesthetics practices operate and grow. Shaped by customer feedback and market momentum, the program now introduces simpler savings, greater benefits transparency and expanded opportunities for practice growth, making it easier for customers to understand, access and maximize the value of their partnership with Al",
                "category": "company",
                "datetime": 1786449600,
                "headline": "Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices"
              },
              {
                "id": 141200626,
                "url": "https://finnhub.io/api/news?id=49ac0507a45d1cb7207a32be4124e84155f52820dbe80fd6ed5d4efd0ede2563",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The pharmaceutical company hopes that another big-time acquisition will pay off.",
                "category": "company",
                "datetime": 1786446300,
                "headline": "AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141176631,
                "url": "https://finnhub.io/api/news?id=ca413707af7b6ebc1e4b5a8d925fc732324d990c17033e1fcd8bfdcb0a5c22ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]",
                "category": "company",
                "datetime": 1786381180,
                "headline": "AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use"
              },
              {
                "id": 141176602,
                "url": "https://finnhub.io/api/news?id=9619ef377aa37b3295cafc7d2a4686061b76f5c87f4c8df7da46959859930693",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.",
                "category": "company",
                "datetime": 1786377692,
                "headline": "Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection"
              },
              {
                "id": 141175296,
                "url": "https://finnhub.io/api/news?id=f343afcf599cec5059f6e3384f6e1fcfe83b4c90004ff60e199ddf20e99103ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock is up just 8% this year and could prove to be an undervalued buy.",
                "category": "company",
                "datetime": 1786370641,
                "headline": "Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?"
              },
              {
                "id": 141174297,
                "url": "https://finnhub.io/api/news?id=69abc7bda0fef2cc41514d6b8a86bc01b40e4cb7b2b108f5ac878016d42a3aad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.",
                "category": "company",
                "datetime": 1786369539,
                "headline": "We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks."
              },
              {
                "id": 141176420,
                "url": "https://finnhub.io/api/news?id=c051b59f5a73b56e38d6aba01c778ec561b3bfd020bd5ce34cb5a2533cb10b81",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Evercore ISI Group  analyst Gavin Clark-Gartner   maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.",
                "category": "company",
                "datetime": 1786363337,
                "headline": "Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260"
              },
              {
                "id": 141173839,
                "url": "https://finnhub.io/api/news?id=cdede5a86a1a9c715bcc2916ec012ef4f51f2e1958b7fa818b04daf0ff357e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.",
                "category": "company",
                "datetime": 1786363255,
                "headline": "3 Beaten-Down Healthcare Stocks to Buy in August"
              },
              {
                "id": 141174738,
                "url": "https://finnhub.io/api/news?id=79f38d590e34e831d31db42477bd1fdbd5b0b46115fb301503409749e238a15b",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share",
                "category": "company",
                "datetime": 1786346565,
                "headline": "Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate"
              },
              {
                "id": 141170024,
                "url": "https://finnhub.io/api/news?id=d0da7ae1c82aa7f3246b7500985fb1b061b1cb20ab34f3c7b72861cac2bd7407",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that “each [portfolio] delivered growth above 20%,” with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure o",
                "category": "company",
                "datetime": 1786318402,
                "headline": "The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call"
              },
              {
                "id": 141152474,
                "url": "https://finnhub.io/api/news?id=3852ba4223d6f6fd4381be34a82f8c1b6dd45b23181cf2e6ab311afb3d93f615",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.",
                "category": "company",
                "datetime": 1786135497,
                "headline": "AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141152475,
                "url": "https://finnhub.io/api/news?id=b90d636c4769ab650549fd4b8dc6d371e94f4881e136739b0611111754981b16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...",
                "category": "company",
                "datetime": 1786133683,
                "headline": "AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed"
              },
              {
                "id": 141150983,
                "url": "https://finnhub.io/api/news?id=dd12bcdfe4ed22cf3954c88504072df39a69214fa699b7fae9f00c2150af3b44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.",
                "category": "company",
                "datetime": 1786127896,
                "headline": "The Two Divergent Paths Priced Into Eli Lilly Stock"
              },
              {
                "id": 141152423,
                "url": "https://finnhub.io/api/news?id=af72a397d825898b459a1a054ad11e152f22a3d67f610472c2aab599efe41d41",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Weekly dividend activity roundup for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786125278,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 9"
              },
              {
                "id": 141151021,
                "url": "https://finnhub.io/api/news?id=db89ffb6a4e42d5346028ad604677dfe666fde3976466e11bfea0e10028f27bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.",
                "category": "company",
                "datetime": 1786121580,
                "headline": "Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised"
              },
              {
                "id": 141144662,
                "url": "https://finnhub.io/api/news?id=c788d44770abb69329f91e62fdaa825f7bcc95adbe6ddc7ed9740f7b0bb37c05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.",
                "category": "company",
                "datetime": 1786116600,
                "headline": "These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks"
              },
              {
                "id": 141146290,
                "url": "https://finnhub.io/api/news?id=073123c4b31e553d2572c2822ba658bac9a5787f0a57ddd4413bf144a3348847",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic",
                "category": "company",
                "datetime": 1786100635,
                "headline": "REGENXBIO Q2 Earnings Call Highlights"
              },
              {
                "id": 141140401,
                "url": "https://finnhub.io/api/news?id=e101b5936974d060a563dddc97f11a0b8de11bef1f7aa6e60687465b8d41392e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.",
                "category": "company",
                "datetime": 1786042973,
                "headline": "Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ..."
              },
              {
                "id": 141137106,
                "url": "https://finnhub.io/api/news?id=13924ec932305c2a9448f9e2ae9ac52f8af0e2e6a13c7132c5bb76ff66330f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JEPI's fat monthly yield has made it a retiree favorite, but a smaller rival running a completely different options playbook has quietly compounded far more wealth over the same period without sacrificing the monthly income routine investors depend on.",
                "category": "company",
                "datetime": 1786032359,
                "headline": "The 6.4% Monthly Payer That Beat JEPI by 8 Points With No NAV Bleed"
              },
              {
                "id": 141137156,
                "url": "https://finnhub.io/api/news?id=2f69e9460fe0aae9ead0dc803c5110b49010b128ce55b4a38234a0a34db793d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.",
                "category": "company",
                "datetime": 1786031340,
                "headline": "ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?"
              },
              {
                "id": 141133236,
                "url": "https://finnhub.io/api/news?id=d05725a4e5530ffbaa9a602865085d7eca56d38ae76b509ab7846a4a82faa6a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2026.",
                "category": "company",
                "datetime": 1786014300,
                "headline": "REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights"
              },
              {
                "id": 141133788,
                "url": "https://finnhub.io/api/news?id=ccfe548320a03015e958d00e621de8931f2aaa56083a349960ae1c56ad152b8d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359351391/image_1359351391.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Discover Seeking Alpha’s July spotlight on top new analysts and highest‑conviction stock ideas—from Strong Sell to Strong Buy.",
                "category": "company",
                "datetime": 1786006800,
                "headline": "Stock Picks From Seeking Alpha's July 2026 New Analysts"
              },
              {
                "id": 141135283,
                "url": "https://finnhub.io/api/news?id=61b54d952a72f4dae3b74529ad2a238f7f8fa29b096a0fde8d3c13db7000a809",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Valhalla--Ny--Usa---May-10--2023-Governo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 million New Yorkers.",
                "category": "company",
                "datetime": 1785987665,
                "headline": "Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'"
              },
              {
                "id": 141130013,
                "url": "https://finnhub.io/api/news?id=7483d7b586d5468d6252462a946d27bac340979c4a16c1f9509dc07c879b992b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "There is no end in sight for the drugmaker's dividend growth streak.",
                "category": "company",
                "datetime": 1785979200,
                "headline": "This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now"
              },
              {
                "id": 141127414,
                "url": "https://finnhub.io/api/news?id=70b784d51037fc27f530c0693cd7ca54aaa42aced8229c9033418c5edab4fcf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.",
                "category": "company",
                "datetime": 1785964991,
                "headline": "Why PFE Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 141126014,
                "url": "https://finnhub.io/api/news?id=4ca154ba64515bee5ba02348b2bcfc96c4b3f716d2aaef53bf1dd2abbbbb6145",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217256698/image_2217256698.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.",
                "category": "company",
                "datetime": 1785945929,
                "headline": "Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan"
              },
              {
                "id": 141122396,
                "url": "https://finnhub.io/api/news?id=e27cb2755c5c26998a75d4cb2de83f1f6b0204bab0546d82cb0ec6f2e4beebbb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.",
                "category": "company",
                "datetime": 1785938426,
                "headline": "Prediction: AbbVie Will End The Year at This Price"
              },
              {
                "id": 141122397,
                "url": "https://finnhub.io/api/news?id=a5d12c161719fec86d0953667d5106489f878b197dcd136d8bded74bb49fddca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1785936603,
                "headline": "Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?"
              },
              {
                "id": 141121210,
                "url": "https://finnhub.io/api/news?id=ded11a9aaaddbe35c2d7f52a8a4439ad63809fe94831a4593b0689c261baaa92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]",
                "category": "company",
                "datetime": 1785932245,
                "headline": "Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout"
              },
              {
                "id": 141121211,
                "url": "https://finnhub.io/api/news?id=06a6c05372c8650453ae2310000521ca952894db264efd78001e09f650b3a829",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Basel convened leading experts from companies such as Roche, Bayer, Novo Nordisk, Galapagos, AbbVie, and Syngenta to tackle the industry's most pressing challenge: ensuring current digital and AI executions rest on solid data foundations while preparing for the next frontier of technological disruption.",
                "category": "company",
                "datetime": 1785931200,
                "headline": "A New Biopharma Roadmap: Zifo's SiEE Basel Event Puts Data Before AI Hype"
              },
              {
                "id": 141116446,
                "url": "https://finnhub.io/api/news?id=4294721d5e797a3d92009c32ef6716dc6e1e8a0b9dc7fd9a3a6b723551b37502",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence. If cleared, BOTOX Cosmetic would be the first neurotoxin approved in the U.S. for this condition, supported by positive Phase 3 trial data. The filing highlights AbbVie’s push to broaden its aesthetics offerings beyond current BOTOX Cosmetic indications. AbbVie (NYSE:ABBV) is drawing fresh attention to its...",
                "category": "company",
                "datetime": 1785881502,
                "headline": "AbbVie (ABBV) Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push"
              },
              {
                "id": 141113199,
                "url": "https://finnhub.io/api/news?id=0f21837584c1a925e9fe4fed0c754b296971f9a558761b1fc426bddbd7a6ffd8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th",
                "category": "company",
                "datetime": 1785872648,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 141113185,
                "url": "https://finnhub.io/api/news?id=ffe8f821463a343289a11f64068bcee41cc91dca55356f4a3d50ffb074e8f0f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.",
                "category": "company",
                "datetime": 1785871390,
                "headline": "The $85 Billion Consolation Prize For JNJ Shareholders"
              },
              {
                "id": 141109964,
                "url": "https://finnhub.io/api/news?id=6e7f4317cb786b7f9728ee04a233d67a2d9a56a04c50fa6ec2539e7df112e8db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785858082,
                "headline": "ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset"
              },
              {
                "id": 141109951,
                "url": "https://finnhub.io/api/news?id=e797e0aa936de6b0064211ba2903917ac54b6d9e07c6a92e8357299462acd0fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph",
                "category": "company",
                "datetime": 1785855413,
                "headline": "Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats"
              },
              {
                "id": 141111550,
                "url": "https://finnhub.io/api/news?id=de33b8a0123d2b292054ba1f29716341249c010c55f9d5ee0e321353a5057f28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212125572/image_2212125572.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "OPKO Health's Q2 results: IP revenue surged on Nicoya deal and FY2026 guidance rose. Click for this OPK stock update.",
                "category": "company",
                "datetime": 1785851748,
                "headline": "OPKO Health: Mazdutide And MDX-2201 Could Change Everything"
              },
              {
                "id": 141108581,
                "url": "https://finnhub.io/api/news?id=da39fad6ce4023618044e99e788b9a7e74dce51c406f6625526fe595c6dd08ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX® Cosmetic would become the first and only neurotoxin indicated for this condition in the U.",
                "category": "company",
                "datetime": 1785844800,
                "headline": "Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence"
              },
              {
                "id": 141108544,
                "url": "https://finnhub.io/api/news?id=3ba73eb480f565d3b222d2e26e21c31875414361f708858d97bc10009ca620bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.",
                "category": "company",
                "datetime": 1785844380,
                "headline": "AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open"
              },
              {
                "id": 141107738,
                "url": "https://finnhub.io/api/news?id=6a988a79719d8712b08fec53bd6f03baac19f7d282b1c392dd4b4c8a6b5c4c65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with moderate to severe pain.3",
                "category": "company",
                "datetime": 1785837660,
                "headline": "UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment"
              },
              {
                "id": 141110843,
                "url": "https://finnhub.io/api/news?id=7456f8076167e76e77ac5caf63b0ea6b2f0e2b83c1251b773058249c5604dfc8",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "https://www.bloomberg.com/news/articles/2026-08-04/abbvie-seeks-at-least-8-billion-in-debt-to-fund-apogee-deal",
                "category": "company",
                "datetime": 1785835511,
                "headline": "'AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal' - Bloomberg"
              },
              {
                "id": 141110844,
                "url": "https://finnhub.io/api/news?id=bf20c9712d90cc85b1006ad550fb7cc02f567dd543b3dd3c61276130ec7e19c0",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic",
                "category": "company",
                "datetime": 1785830487,
                "headline": "AbbVie's Allergan Aesthetics Receives FDA Acceptance For Review For Its Supplemental Biologics License Application For BOTOX Cosmetic"
              },
              {
                "id": 141110845,
                "url": "https://finnhub.io/api/news?id=5c9038358547dbb1595d9f37867ff7ff82bd64ab691560cd542b554b53dadf2c",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Guggenheim  analyst Vamil Divan   maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.",
                "category": "company",
                "datetime": 1785829730,
                "headline": "Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288"
              },
              {
                "id": 141110846,
                "url": "https://finnhub.io/api/news?id=28a9806e01411afa1527d3c7fecc1579952b1919d1cb985d09f8358c321950b5",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase3 ACHIEVEI and ACHIEVEII studies.CDA-AMC recommendation recognizes the need for",
                "category": "company",
                "datetime": 1785824177,
                "headline": "AbbVie Says Canada's Drug Agency Recommends UBRELVY Be Reimbursed With Conditions By Public Drug Plans For Acute Treatment Of Migraine In Adults"
              },
              {
                "id": 141106141,
                "url": "https://finnhub.io/api/news?id=dbf4b6019f91f02858a1ece648ddae5789111607280907eb8c2c8f7b58dbb7e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.",
                "category": "company",
                "datetime": 1785821400,
                "headline": "More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not"
              },
              {
                "id": 141111671,
                "url": "https://finnhub.io/api/news?id=9b556dc9deb3a11dc5a1c80e204ef78f32d01b2dca5bc25093778d87412b676c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Deal or no deal, mere talks between Astrazeneca and Bristol-Myers point to one of the global pharma industry’s biggest themes.",
                "category": "company",
                "datetime": 1785816060,
                "headline": "‘Huh?’ Markets React to AstraZeneca’s Megadeal Talks With Bristol Myers"
              },
              {
                "id": 141104215,
                "url": "https://finnhub.io/api/news?id=f90be4844bbfd3be905a623ee6e1e0773889b20041c5133207617d9f83f6a119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.",
                "category": "company",
                "datetime": 1785798877,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off"
              },
              {
                "id": 141102901,
                "url": "https://finnhub.io/api/news?id=d4dad4b699c25939294901b37ea777c978aeb76e6fceb2ae6fa35fdbcd0e2d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.",
                "category": "company",
                "datetime": 1785791142,
                "headline": "AbbVie's Growth Now Leans On A Single Molecule"
              },
              {
                "id": 141110847,
                "url": "https://finnhub.io/api/news?id=b6fc2459055243ef0a7a91281b2fd5ab1d52157cddc4753f6f8a82c4c3216e65",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Canaccord Genuity  analyst Gary Nachman   maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $282 to $290.",
                "category": "company",
                "datetime": 1785777497,
                "headline": "Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $290"
              },
              {
                "id": 141100779,
                "url": "https://finnhub.io/api/news?id=e3ca59cf6e34e30471a6601a0ba277a531ad295e5dc8b9b29bb5937fd95a3983",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to",
                "category": "company",
                "datetime": 1785776400,
                "headline": "Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight"
              },
              {
                "id": 141111662,
                "url": "https://finnhub.io/api/news?id=6e71450bdf5b7604e689e41936a1f88574d1e3d7cf4c5df85452b935df8a116d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).",
                "category": "company",
                "datetime": 1785775200,
                "headline": "The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure"
              },
              {
                "id": 141100727,
                "url": "https://finnhub.io/api/news?id=93beca83add4b02ad8b271b7b1ba0242659fa4ae9be591f4bd91c8198b9827db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.",
                "category": "company",
                "datetime": 1785773653,
                "headline": "Stocks mixed as AstraZeneca merger talk dents FTSE 100"
              },
              {
                "id": 141104231,
                "url": "https://finnhub.io/api/news?id=f5640ff67b7f0dff8d4acb32c1dad754ffcea965097e85d4f8866ff61c150b05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.",
                "category": "company",
                "datetime": 1785772900,
                "headline": "What Are Wall Street Analysts' Target Price for AbbVie Stock?"
              },
              {
                "id": 141100781,
                "url": "https://finnhub.io/api/news?id=af315b5b99b89c0c23ee46c049e3ac334340df5fe0be3a197bed9cfea6d9969e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) reported another \"strong\" quarter operationally, with investor attention increasingly",
                "category": "company",
                "datetime": 1785772552,
                "headline": "AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says"
              },
              {
                "id": 141104216,
                "url": "https://finnhub.io/api/news?id=d77b4af73a0ae6b155f2e7af6fd9eb9d1432425df71bb6ac044b62a72ae183e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]",
                "category": "company",
                "datetime": 1785768954,
                "headline": "Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison"
              },
              {
                "id": 141100782,
                "url": "https://finnhub.io/api/news?id=e60fb40d8554b9209556b6ebff14bc51e6b44d0abf62a249f1194ef641a11e7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.",
                "category": "company",
                "datetime": 1785765600,
                "headline": "ABBV Q2 Earnings Call Balances Growth With Apogee Dilution"
              },
              {
                "id": 141110823,
                "url": "https://finnhub.io/api/news?id=59536925328acfcf2795e77fa358abce85166756e7bdad705b2881275bc525f0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Merger-And-Acquisition-Business-Corporat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.",
                "category": "company",
                "datetime": 1785762819,
                "headline": "AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus"
              },
              {
                "id": 141098760,
                "url": "https://finnhub.io/api/news?id=295300f8195581d504cda12b4ff55830b229bb2bd3b6d33c887afd23ad24ee10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Your portfolio could be paying you quarterly income right now from three companies that have raised their dividends for decades straight, but the next ex-dates are approaching fast and missing them means waiting another quarter to collect.",
                "category": "company",
                "datetime": 1785760259,
                "headline": "3 Top Dividend Stocks to Buy Before Their Next Payout"
              },
              {
                "id": 141099326,
                "url": "https://finnhub.io/api/news?id=cc2662e857815e4ce5bff63b03718501328f075fffcc39c614651be14387b757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156417320/image_2156417320.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie Inc. stock fell 6.2% after a 52-week high despite strong Q2 earnings; Rinvoq and Elahere sales surged. Click for this ABBV earnings udpate.",
                "category": "company",
                "datetime": 1785751531,
                "headline": "AbbVie: Strong Q2 And New Catalysts Keep Me Bullish"
              },
              {
                "id": 141100269,
                "url": "https://finnhub.io/api/news?id=d909bb1dbbac5c954ada51e140db524a33f0b187ed642a0056c443ac1d48cd64",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $265 to $285.",
                "category": "company",
                "datetime": 1785746814,
                "headline": "Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $285"
              },
              {
                "id": 141100783,
                "url": "https://finnhub.io/api/news?id=cf9b73def0f1a76b11756132579876cdade6b5662526983f33abbb87f575f3f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.",
                "category": "company",
                "datetime": 1785682800,
                "headline": "AbbVie Quietly Solved Its Biggest Problem—Now What?"
              },
              {
                "id": 141084258,
                "url": "https://finnhub.io/api/news?id=8f647e1c9b87d7a0145a50ec9121f690d7715f4964a424b15a582e40e09291e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.",
                "category": "company",
                "datetime": 1785542481,
                "headline": "Why AbbVie Stock Slumped Today"
              },
              {
                "id": 141082601,
                "url": "https://finnhub.io/api/news?id=65c6bb9a48a8a6767c6d8ec539b3c82814034592c097522a8ce51873039f8ab0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ (upadacitinib) as the first systemic treatment in the EU for non segmental vitiligo. The decision also covers RINVOQ as a systemic option for severe alopecia areata in adults and adolescents. These approvals expand RINVOQ’s labeled uses in Europe and add new indications in dermatology and immunology. For investors following AbbVie, this move adds fresh detail to the story around its immunology franchise. The company...",
                "category": "company",
                "datetime": 1785532221,
                "headline": "AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia"
              },
              {
                "id": 141082602,
                "url": "https://finnhub.io/api/news?id=3c2eafd52a67ba1afd7b285cc44856f94f72f58d43ea6fe3f5e1fff4217847eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc (ABBV) beats expectations with 10.2% revenue growth, raises full-year guidance, and showcases promising pipeline developments despite Humira's decline.",
                "category": "company",
                "datetime": 1785531661,
                "headline": "AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ..."
              },
              {
                "id": 141081525,
                "url": "https://finnhub.io/api/news?id=21af69931f0ca29d34869ccbb2de126b8102a3e78424cef591d53d9c6d3cdd39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics.",
                "category": "company",
                "datetime": 1785518520,
                "headline": "AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling."
              },
              {
                "id": 141082293,
                "url": "https://finnhub.io/api/news?id=47bdb4f92c4fcd1ac1e342ca45dd31e6bd1624882562a0dd56dddf3ee970f21b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391441819/image_1391441819.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Viatris is rated a Sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. Read more on VTRS stock here.",
                "category": "company",
                "datetime": 1785518138,
                "headline": "Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run"
              },
              {
                "id": 141081519,
                "url": "https://finnhub.io/api/news?id=092378f14fbaf65df765133c573286e97c0df60a3952b635aafd21dc6def0b1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.",
                "category": "company",
                "datetime": 1785517860,
                "headline": "ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down"
              },
              {
                "id": 141080313,
                "url": "https://finnhub.io/api/news?id=cf326811101db0e4abbede08efd4c6c0943d35e213367c69ebda4a76b979e103",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Moby summary of AbbVie Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785516659,
                "headline": "AbbVie Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141081925,
                "url": "https://finnhub.io/api/news?id=bf085e574bf0c493b0803a1456001c8a53278d8a528a8003314889bb252732ab",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie Inc. (ABBV) Q2 2026 Earnings Call July 31, 2026 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert...",
                "category": "company",
                "datetime": 1785515013,
                "headline": "AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141080308,
                "url": "https://finnhub.io/api/news?id=3c4393408a8fd4ee84090b505d6f9b4c7f4085acb7a7f867e6203122edc98ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj",
                "category": "company",
                "datetime": 1785513926,
                "headline": "Top Midday Stories: Apple Shares Fall on Weak Guidance; Amazon Q2 EPS Beats Estimates as AWS Sales Surge"
              },
              {
                "id": 141083123,
                "url": "https://finnhub.io/api/news?id=2db5f0a66870fda68bc9aa8df97e26f93d72a67888ce2ee1e469341d119c13ac",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of $436.27 billion. \nBuying",
                "category": "company",
                "datetime": 1785513643,
                "headline": "Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today"
              },
              {
                "id": 141080311,
                "url": "https://finnhub.io/api/news?id=065f4a1a3bb93cd6a66fec993d61203ed8bd6bcd95a567c41c0bd878c2cd24c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution",
                "category": "company",
                "datetime": 1785512731,
                "headline": "AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition"
              },
              {
                "id": 141080309,
                "url": "https://finnhub.io/api/news?id=8a3534bd4009b69a71a93dd71f5bba954daf75fe76084b26305e55bb39330da3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Earnings Data Deluge",
                "category": "company",
                "datetime": 1785511680,
                "headline": "Earnings Data Deluge"
              },
              {
                "id": 141078975,
                "url": "https://finnhub.io/api/news?id=35c14c210bf3b2f190b4af5c8b89d12f9f05e9c2d5091050cb7bd375e52ef2e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p",
                "category": "company",
                "datetime": 1785510268,
                "headline": "AbbVie Q2 Earnings Call Highlights"
              },
              {
                "id": 141078976,
                "url": "https://finnhub.io/api/news?id=b7d97bc3de80d7b59d4f09531b8def1b8ecf3cf0334ce71e784415c96c37dc5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates",
                "category": "company",
                "datetime": 1785510228,
                "headline": "AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition"
              },
              {
                "id": 141078967,
                "url": "https://finnhub.io/api/news?id=2f80b7fd914d4836dd5732378c775b0167fc597642d185d22ef40c9454c93646",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Despite some mid-week turbulence, we're trading fairly even with where we were as of mid-day Monday.",
                "category": "company",
                "datetime": 1785508440,
                "headline": "Pre-Market Trading Up in Final Session of the Week"
              },
              {
                "id": 141078938,
                "url": "https://finnhub.io/api/news?id=904056145b3b700f5b4951a026912ba2b2f2d20293cb187a0d707165b290f859",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.",
                "category": "company",
                "datetime": 1785507981,
                "headline": "The Signs Before Eli Lilly Stock Surged Were All On The Record"
              },
              {
                "id": 141078939,
                "url": "https://finnhub.io/api/news?id=6fcc1f678f181e34376a4202dbe1cd843f51aa42067d5392c634aac3c29f9081",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.",
                "category": "company",
                "datetime": 1785506858,
                "headline": "LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15%"
              },
              {
                "id": 141078980,
                "url": "https://finnhub.io/api/news?id=014831428409dbba11f5692e6c73b19da31aeaa3a7ac48ece993985543f27214",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1785506402,
                "headline": "AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141080716,
                "url": "https://finnhub.io/api/news?id=400c1e253059928ecd67705b55506f50b8f112b556e3bea7f2de09df91a3664f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Amazon-Logo-On.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cycle highs.",
                "category": "company",
                "datetime": 1785505365,
                "headline": "Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion"
              },
              {
                "id": 141083125,
                "url": "https://finnhub.io/api/news?id=124c8531440585f041703b9413c14bc51c8da14ba7b5e2d00644609cd0ab8751",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Ipo-Initial-Public-Offering--Business-Ma.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.",
                "category": "company",
                "datetime": 1785505029,
                "headline": "Moleculin Biotech Stock Is Sinking Friday: What's Going On?"
              },
              {
                "id": 141077988,
                "url": "https://finnhub.io/api/news?id=1ca075bc1a56b6dcf424fd797aa4ffc47a3c2f453052f6faf045443e0afb79f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share",
                "category": "company",
                "datetime": 1785504002,
                "headline": "AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal"
              },
              {
                "id": 141077989,
                "url": "https://finnhub.io/api/news?id=b3ee4a487bdd88722763b035259a6f911b58e271a762fbda286221ae3b9b4be8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785502779,
                "headline": "AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue"
              },
              {
                "id": 141078981,
                "url": "https://finnhub.io/api/news?id=463a69dba7aff2143b11d7e08a0df0d5a21fc293541a944b75ac8b355e0243ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785502502,
                "headline": "AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates"
              },
              {
                "id": 141077867,
                "url": "https://finnhub.io/api/news?id=84f0275a275618ec204a5a85015de38502cbd34f3bc57cbee2dc1cd924dd6bc9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1785502028,
                "headline": "Update: Amazon Overperformance Lifts US Equity Futures Pre-Bell Amid Potential Expansion of Middle East Conflict to Egypt"
              },
              {
                "id": 141077642,
                "url": "https://finnhub.io/api/news?id=3223cbf246df2f33c69539037f774a50260cd33d10286f045a518ad8062cad57",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Discover the top S&P500 movers in Friday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1785501301,
                "headline": "Get insights into the top movers in the S&P500 index of Friday's pre-market session."
              },
              {
                "id": 141077991,
                "url": "https://finnhub.io/api/news?id=a72a9ef1f80c49cf023dc84c5c3fbc9b8cd68aa14f354e2826cb1f446f3ee4b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie  shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook.  Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet.  AbbVie  posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.",
                "category": "company",
                "datetime": 1785501060,
                "headline": "AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance."
              },
              {
                "id": 141077992,
                "url": "https://finnhub.io/api/news?id=8ecf5c62b72c4d15c0daf04bb83e4bedff34a151a5bb146c221727b9ff2d389c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.",
                "category": "company",
                "datetime": 1785500834,
                "headline": "AbbVie shares fall on earnings miss and weak guidance"
              },
              {
                "id": 141077567,
                "url": "https://finnhub.io/api/news?id=29cd62e5bcd61d77eb45ae5acdd626e987475550af11a1b82822076dbcce5389",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "AbbVie Q2 earnings match estimates, but stock dips 4% on Apogee Therapeutics acquisition news amid steady results.",
                "category": "company",
                "datetime": 1785500429,
                "headline": "AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results"
              },
              {
                "id": 141077109,
                "url": "https://finnhub.io/api/news?id=f16d5a2dc9b6a4824034e9a6c0d771a4a457d491209a6f45740cd61bdbd2cfc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The benchmark US stock measures were tracking in the green before the open Friday as Amazon's (AMZN)",
                "category": "company",
                "datetime": 1785498389,
                "headline": "Stocks Rise Pre-Bell as Amazon Results Lift AI Trade Sentiment"
              },
              {
                "id": 141083126,
                "url": "https://finnhub.io/api/news?id=83fc956e5a4b5a60210f7dcb4a0d129e7ab44a033462a71256b10e75d4b2423c",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of $17.200 billion vs $17.322 billion analyst estimate.",
                "category": "company",
                "datetime": 1785497257,
                "headline": "Conference Call:\nAbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est"
              },
              {
                "id": 141083127,
                "url": "https://finnhub.io/api/news?id=c2401c82c6bbe855e37c2157755df80079151eef2330f3f3b29d915bc8f56a3d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.",
                "category": "company",
                "datetime": 1785492987,
                "headline": "AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat"
              },
              {
                "id": 141083128,
                "url": "https://finnhub.io/api/news?id=d31424c1a9ba8afbb685c81cb6bb3d4767b218c2adb1757bb2c9fa154f145771",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "https://edge.media-server.com/mmc/p/m9vcn44b/",
                "category": "company",
                "datetime": 1785490226,
                "headline": "AbbVie Exec Says Now Expect Total Annual Net Revenue Of ~$67.6B, Increase Of $300M Versus Previous Forecast"
              },
              {
                "id": 141083129,
                "url": "https://finnhub.io/api/news?id=fd9e6b6226975918e236eeac92f55ceefcf946ab34c4ff5eda4218a4f37a5b1a",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) lowers FY2026 Adj EPS guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 analyst estimate..",
                "category": "company",
                "datetime": 1785486104,
                "headline": "CORRECTION: AbbVie Lowers FY2026 Adj EPS Guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 Est"
              },
              {
                "id": 141083130,
                "url": "https://finnhub.io/api/news?id=26e10aae59e7b01e8e02d1c8556f4a0c9f09a7781d9f9dab351b59b001e855ac",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) reported quarterly earnings of $3.65 per share which beat the analyst consensus estimate of $3.60 by 1.39 percent. This is a 22.9 percent increase over earnings of $2.97 per share from the same period",
                "category": "company",
                "datetime": 1785484121,
                "headline": "AbbVie Q2 Adj. EPS $3.65 Beats $3.60 Estimate, Sales $16.990B Beat $16.765B Estimate"
              },
              {
                "id": 141072918,
                "url": "https://finnhub.io/api/news?id=14dc8fa65654e512f70d4fda3e23e46128c2ac9e31b7c4e11adb51ad16cd7269",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Asking for a Trend Host Josh Lipton previews what investors should be on the lookout for on Friday, July 31, including earnings from energy giants Exxon (XOM), Chevron (CVX), and biopharma AbbVie (ABBV) as well as the latest read on consumer sentiment.",
                "category": "company",
                "datetime": 1785448860,
                "headline": "Friday's market movers: Oil earnings and consumer sentiment data"
              },
              {
                "id": 141066701,
                "url": "https://finnhub.io/api/news?id=6c58f0d6da027f5209d141c1ef2370eb95d32ae48782c108da3d5b120b00ed88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Rinvoq, Comirnaty and Opzelura have all received their own EC approvals this week.",
                "category": "company",
                "datetime": 1785423940,
                "headline": "EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals"
              },
              {
                "id": 141066702,
                "url": "https://finnhub.io/api/news?id=c1a81224db58e623178488a479aee7585a58116ec82004d3c0df2ac88b00d9bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for.",
                "category": "company",
                "datetime": 1785420302,
                "headline": "What To Expect From AbbVie’s (ABBV) Q2 Earnings"
              },
              {
                "id": 141064881,
                "url": "https://finnhub.io/api/news?id=8ee9be09420ca3ed72c8b63e7edf7b20b0f876a3dfc6832ec20215871d382e2d",
                "image": "https://www.chartmill.com/images/uploads/cannabis_theme_f843462963.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "While pure-play cannabis stocks struggle, defensive opportunities emerge in pharma, staples, and industrial firms like AbbVie, Altria, and Jazz Pharma with strong profitability and value.",
                "category": "company",
                "datetime": 1785413140,
                "headline": "Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays"
              },
              {
                "id": 141065442,
                "url": "https://finnhub.io/api/news?id=5f513d8aac12ed99fa2513604c134eec1c8eaf449e3e76734d40195a638efb9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 19, 2026, with exclusive JUVÉDERM® offers for Allē Members. Allergan Aesthetics invites aesthetic providers and consumers to join in celebrating JUVÉDERM®'s continued aesthetics leadership as the number one chosen hyaluronic acid (HA) dermal filler collection in the U.S.*,1",
                "category": "company",
                "datetime": 1785412800,
                "headline": "JUVÉDERM® Day Returns to U.S. on August 19"
              },
              {
                "id": 141058324,
                "url": "https://finnhub.io/api/news?id=15c4df4c5fb54cf1ba96872499789cc422bc41568843a346462416b65eec3566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "But is that performance sustainable?",
                "category": "company",
                "datetime": 1785360000,
                "headline": "Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now"
              },
              {
                "id": 141057017,
                "url": "https://finnhub.io/api/news?id=e2cfd77352aedb0d87503712841214980f53bb4ab61b29927df9b64aee78b575",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.",
                "category": "company",
                "datetime": 1785348670,
                "headline": "The Real Price of AbbVie Stock Is Cheaper Than You Think"
              },
              {
                "id": 141055722,
                "url": "https://finnhub.io/api/news?id=6344153d97a5d0b9c3e6164f8d007b3dc14a32a4ecff0263cc00d944695d9d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie still looks like a compelling buy at its all-time high.",
                "category": "company",
                "datetime": 1785344178,
                "headline": "AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?"
              },
              {
                "id": 141051551,
                "url": "https://finnhub.io/api/news?id=52069f3a25acd2269ac3042a98b22b4096429e52957c77caa9a9c2ca47b141c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie stock has delivered strong returns over the past five years, yet the current valuation picture is split, with the intrinsic value estimate pointing to upside while market multiples suggest the shares screen rich. AbbVie has returned 172.0% over five years, which puts extra focus on whether the current price still offers an attractive entry for new capital. Recent European approvals for RINVOQ and Allergan Aesthetics' Boey can support expectations for future cash flows, while mixed...",
                "category": "company",
                "datetime": 1785316228,
                "headline": "AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run"
              },
              {
                "id": 141058776,
                "url": "https://finnhub.io/api/news?id=dfd3cd04cb31c055bb002756e92c7825d34d1fdcdb9c60dbd0bc06d6265c8057",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Barclays  analyst Emily Field   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $275 to $300.",
                "category": "company",
                "datetime": 1785311580,
                "headline": "Barclays Maintains Overweight on AbbVie, Raises Price Target to $300"
              },
              {
                "id": 141051094,
                "url": "https://finnhub.io/api/news?id=3362d57cf865944f735f12e8966b6a1467613672ba4d1ef0d145a4d4a6a0c324",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata (AA).1",
                "category": "company",
                "datetime": 1785308400,
                "headline": "AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata"
              },
              {
                "id": 141051093,
                "url": "https://finnhub.io/api/news?id=5541ab38e7cdf3061e53354715cd59a6ef9646e8707eee436a81ad24d2a0f068",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemic therapy.1 With this approval, RINVOQ is now the first and only systemic medication approved in the European Union for NSV, the most common form of vitiligo.2",
                "category": "company",
                "datetime": 1785308400,
                "headline": "AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo"
              },
              {
                "id": 141057973,
                "url": "https://finnhub.io/api/news?id=d2cd32fbbfda3153a0cde8cbe47e51cc4aecd15c201ffdd168c8fb785d2c51b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Dallas--Tx---August-5--2022-Senator-Rick.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Scott warns China’s new drug rules could threaten U.S. medicine security, urging America to reduce reliance on Beijing.",
                "category": "company",
                "datetime": 1785307896,
                "headline": "Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'"
              },
              {
                "id": 141049956,
                "url": "https://finnhub.io/api/news?id=c11f70f6248138fa74face27e195c6ee05be83507d3b26659819389f8909ebe7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago, investors were restless. The two drugs carrying the company were doing fine, but everyone already knew that, and the market wanted a new reason to invest. Goldman Sachs went ...",
                "category": "company",
                "datetime": 1785295980,
                "headline": "Goldman Sachs uncovers key AbbVie stock signals before earnings"
              },
              {
                "id": 141058778,
                "url": "https://finnhub.io/api/news?id=fb06d7ab57159e178e0b2a19e257ef34df38d0c33567258a7e8ec4372b4bb027",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV)The approval is supported by data from the Phase 3 Viti-Up clinical",
                "category": "company",
                "datetime": 1785294337,
                "headline": "AbbVie's RINVOQ Wins European Commission Approval For Non-Segmental Vitiligo, First Systemic Medication Approved In EU For This Condition"
              },
              {
                "id": 141047303,
                "url": "https://finnhub.io/api/news?id=556426890a3fac26e5447912eb362cc02010df281b0dcb32f90c4409a7a36c9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.",
                "category": "company",
                "datetime": 1785271965,
                "headline": "What Johnson & Johnson Stock Told You Before It Surged"
              },
              {
                "id": 141047304,
                "url": "https://finnhub.io/api/news?id=964cb7fb943f3d27b92bfa4cd03543b70ad5d97017a3e0c9b5c997db08924eeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.",
                "category": "company",
                "datetime": 1785271282,
                "headline": "Does Eli Lilly Stock Actually Diversify Your Portfolio?"
              },
              {
                "id": 141046317,
                "url": "https://finnhub.io/api/news?id=94ec934ac7182b360928921fb093fe8b32d0201037b531cdc375e9de346bca87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there.  The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics.  The $10.9 billion deal would strengthen AbbVie's immunology pipeline.",
                "category": "company",
                "datetime": 1785264011,
                "headline": "Botox Maker Tops Buy Point, But Here Comes The Earnings Report"
              },
              {
                "id": 141045221,
                "url": "https://finnhub.io/api/news?id=aed8f8ea06ef7fad60e0a5b472bd22b69426b946331c27e18ddba12db744ec24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.",
                "category": "company",
                "datetime": 1785258596,
                "headline": "3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st"
              },
              {
                "id": 141046312,
                "url": "https://finnhub.io/api/news?id=c28aa1c884cffdf993088c8b520ca68dbb6e087a14c00a11fcf3e0a0dd7be102",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.",
                "category": "company",
                "datetime": 1785258360,
                "headline": "Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?"
              },
              {
                "id": 141044381,
                "url": "https://finnhub.io/api/news?id=d30853e65c00378415d30d59a5967ff2f900939f6907ae3ee97252353d3efa08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the next decade.",
                "category": "company",
                "datetime": 1785254149,
                "headline": "Prediction: This ‘Boring’ Dividend ETF Secretly Rides the AI Trade and Out-Earns Your High-Yield Fund by 2036"
              },
              {
                "id": 141043605,
                "url": "https://finnhub.io/api/news?id=a4e736a3943de92c3e20fe48a9e14561506db203f58dc45385bcab5c4e89fedc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.",
                "category": "company",
                "datetime": 1785247620,
                "headline": "Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?"
              },
              {
                "id": 141043613,
                "url": "https://finnhub.io/api/news?id=40990baf1b73620c80138e2cefd638ab9f0b8ee3c0eb323e7f8610f9347c1f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785247218,
                "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release"
              },
              {
                "id": 141042267,
                "url": "https://finnhub.io/api/news?id=8eb48457e30ed759574902fad91ecc34d75054fa92fff08f027b6ddf02e62c26",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329696857/image_1329696857.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.",
                "category": "company",
                "datetime": 1785231217,
                "headline": "Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)"
              },
              {
                "id": 141038095,
                "url": "https://finnhub.io/api/news?id=2f54abc41486df4873af5700d58fb334ed98a0a9651628208a2a7a80f3b0f840",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The recent rally could pave the way for \"sell the news\" volatility, but don't let this scare you out of a long-term position.",
                "category": "company",
                "datetime": 1785193500,
                "headline": "Should You Buy AbbVie Stock Hand Over Fist Before July 31?"
              },
              {
                "id": 141037135,
                "url": "https://finnhub.io/api/news?id=f039384443066be35bc6ced345a619fa1e6911431bbd02d74d2a8573ae541097",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.",
                "category": "company",
                "datetime": 1785182092,
                "headline": "The Engine Behind ABBV Stock Has Real Parts"
              },
              {
                "id": 141037136,
                "url": "https://finnhub.io/api/news?id=1962630925adf572941ee3d09545871641e85445ce685d06cecba1d3bddbddb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.",
                "category": "company",
                "datetime": 1785180480,
                "headline": "UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch"
              },
              {
                "id": 141036037,
                "url": "https://finnhub.io/api/news?id=2cc61cdbabe57465c6369f88d1cd57b760ec36da2bc51946d6d2f08f0584f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.",
                "category": "company",
                "datetime": 1785177225,
                "headline": "Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips"
              },
              {
                "id": 141035012,
                "url": "https://finnhub.io/api/news?id=ea501f01f1f94e7fc4f83cb68bde7d8193d75c7629f1a619e9a4ba20eeb05a5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "S&P 500 companies' second-quarter earnings growth reached 70%, driven by the information technology",
                "category": "company",
                "datetime": 1785172570,
                "headline": "S&P 500 Second-Quarter Earnings Growth Reaches 70%, Oppenheimer Says"
              },
              {
                "id": 141033665,
                "url": "https://finnhub.io/api/news?id=226e97769226d352193ee468abc933e80443ec0634412daea81166b5b2cba6ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.",
                "category": "company",
                "datetime": 1785166830,
                "headline": "Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck"
              },
              {
                "id": 141032906,
                "url": "https://finnhub.io/api/news?id=f0d659a1185e8bf25d2be2fd5742b5689573b66b302e1d77ed50a29c82a6f20b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "CAMBRIDGE, Mass., July 27, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition.",
                "category": "company",
                "datetime": 1785155400,
                "headline": "Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer"
              },
              {
                "id": 141033829,
                "url": "https://finnhub.io/api/news?id=f44986411b5d5c5246d9ff515ae37c06ae04189d71b1cbe690556f104ea78a28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.",
                "category": "company",
                "datetime": 1785147360,
                "headline": "Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO"
              },
              {
                "id": 141031076,
                "url": "https://finnhub.io/api/news?id=62173fbda2301693a92f3d5da56390b4ea3db8e08c290385b475eabf6e1d5a7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.",
                "category": "company",
                "datetime": 1785135053,
                "headline": "Johnson & Johnson Now Leads Its Pitch With An Oncology Bet"
              },
              {
                "id": 141028474,
                "url": "https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Dividend Kings beat SPY in June–July, reclaiming a YTD lead.",
                "category": "company",
                "datetime": 1785093714,
                "headline": "Best Dividend Kings: July 2026"
              },
              {
                "id": 141023888,
                "url": "https://finnhub.io/api/news?id=0e7c8b9ce48492e0870a97c7e8778cdbf2f0ff180e2b5db500c5b8c844969d64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Both have very promising futures.",
                "category": "company",
                "datetime": 1785060420,
                "headline": "Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?"
              },
              {
                "id": 141020270,
                "url": "https://finnhub.io/api/news?id=7f9ee9e9891472b3ca8091ba21bc032ee3ef7180d7a8dcfe3d6ab7139cd24513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.",
                "category": "company",
                "datetime": 1785019617,
                "headline": "Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75?"
              },
              {
                "id": 141017675,
                "url": "https://finnhub.io/api/news?id=3769ab2c0ea83f99ca7f597ad794b480628f778f45681fcadd0260d799ed512b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its overall survival primary endpoint, raising fresh questions about the drug's long term commercial potential. See our latest analysis for AbbVie. Against this backdrop, AbbVie’s share price has had a strong run, with a 30-day share price return of 10.42% and a 90-day share price return of 30.52%. Its 1-year total shareholder return of 40.53% highlights momentum...",
                "category": "company",
                "datetime": 1784995784,
                "headline": "AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback"
              },
              {
                "id": 141016843,
                "url": "https://finnhub.io/api/news?id=c8f64aaf8ca368f47b9c370c2b9d1f1ca3af5230aa897d88c88c075e19d32ed7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.",
                "category": "company",
                "datetime": 1784990100,
                "headline": "Why Wall Street Can't Get Enough of This Dividend King"
              },
              {
                "id": 141016864,
                "url": "https://finnhub.io/api/news?id=02a7054929fccd13b94135fcc42ef9eaf195056dd9ae3898a266d92a88bdf526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.",
                "category": "company",
                "datetime": 1784989802,
                "headline": "Johnson & Johnson Is Becoming A Narrower Company Than You Bought"
              },
              {
                "id": 141016653,
                "url": "https://finnhub.io/api/news?id=2a9a468b4cda06411e0b3358a8f32ec8ca05e55f439a793c6c9ac9170bb0c9f1",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Wall Street Week Ahead: key earnings (AAPL, MSFT, META), Fed decision, GDP/PCE and IPOs—plus volatility, dividends and RSI screens. See more here.",
                "category": "company",
                "datetime": 1784977200,
                "headline": "Big Tech Earnings, Fed's Interest Rate Decision To Keep Next Week Busy"
              },
              {
                "id": 141012914,
                "url": "https://finnhub.io/api/news?id=9968dc5f0a39d2efae9a5c37aa5e7f90e134329e0f47c7edebe1e3236858774a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Just over a month since its initial public offering,  SpaceX  has delivered one of the weakest post-debut performances of any major U.S. listing since the end of the 2008-2009 financial crisis.  A Barron’s analysis found that the stock performed worse than 90% of other U.S. IPOs with market capitalizations of $1 billion or more since July, 2009.  Over the first 27 trading days,  SpaceX  was down 23% from its first day closing price of $161.",
                "category": "company",
                "datetime": 1784933040,
                "headline": "SpaceX Lands With a Thud"
              },
              {
                "id": 141007742,
                "url": "https://finnhub.io/api/news?id=1a4bd9a8e927b4e383f7109324d5417675ca77a48f556859be0ac2e47c6b2f72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.",
                "category": "company",
                "datetime": 1784903700,
                "headline": "J&J's Innovative Medicine Unit Proves Its Resilience in Q2"
              },
              {
                "id": 141006432,
                "url": "https://finnhub.io/api/news?id=8967641ac31cb8a4821e2a74c19e7270b7c5be7a5db018c5340e01a35ad83335",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784901612,
                "headline": "AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"
              },
              {
                "id": 141005874,
                "url": "https://finnhub.io/api/news?id=36c987ce04ee75dd31cd8b088c5db92bbebf79f032f9e455b0129572dcb17c89",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1627315719/image_1627315719.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie offers a 2.7% forward dividend yield, outperforming peers by 68%, and maintains a 12-year streak of dividend growth. Find out why ABBV stock is a buy.",
                "category": "company",
                "datetime": 1784889960,
                "headline": "AbbVie: A Dividend Fortress At An Appealing Price Tag"
              },
              {
                "id": 141005736,
                "url": "https://finnhub.io/api/news?id=b0eb0f2c25c6209acafa711d38d4f6710c4762d68b8d1a160f1f2a1dac515ac4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Experts-Urge-Seniors-to-Stay-Vigilant.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie shares gained 1.4% to close at $256.92 on Thursday while Transocean shares rose 0.4% to settle at $5.32 during the session.",
                "category": "company",
                "datetime": 1784879595,
                "headline": "Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141005737,
                "url": "https://finnhub.io/api/news?id=09b0ee23712127e790437bd7239e1db83cc0d6bbe776a957098f94fa4e6d192b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.",
                "category": "company",
                "datetime": 1784874313,
                "headline": "Two Years to Build or Pay 200% — Which US Pharma Stocks Win?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 188,
            "discarded_article_count": 158
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.3,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 5374446.666666667,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 4639500,
              "avg_vol_20": 5375250,
              "avg_vol_30": 5374446.666666667,
              "range_pct_10": 0.0944293513899968,
              "range_pct_20": 0.09914704480476481,
              "range_pct_30": 0.09914704480476481,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.863251658775415,
              "dist_to_20d_high": 0.00938426739447423,
              "down_shrink_days": 3,
              "breakout_level_20d": 267.47,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.9524172059383328
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.0981658400575878,
              "turnoverUsdM": 1360.675532646,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.ABBV",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 253.8414,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.2,
            "take_profit_price": 278.208,
            "target_multiplier": 1.9,
            "technical_strength": 1.65,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.1963316801151755,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 5.5593,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.1
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 109.26
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0275
    },
    "kdj": {
      "d": 72.08,
      "j": 102.61,
      "k": 82.25,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 56.18
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 52716100,
      "recentSlope": 1598140,
      "previousSlope": -674160
    },
    "rsi": 74.35,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 243.5518,
      "position": "SAR喺價下",
      "distancePct": 8.08,
      "previousTrend": "上升"
    },
    "ma50": 247.9872,
    "macd": {
      "macd": 3.460149419317929,
      "trend": "強烈看漲",
      "signal": 2.1005060912395246,
      "histogram": 1.3596433280784046
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 253.5747,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 4
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.95,
      "score": 4,
      "avgVolume": 5422270,
      "currentVolume": 5135400
    },
    "derived": {
      "ma20": 253.294,
      "ma50": 247.9872,
      "prevClose": 261.83,
      "avgVolume10": 4659970,
      "avgVolume20": 5422270,
      "changePercent": 1.2,
      "avgVolumeForScore": 5422270
    },
    "ma_cross": {
      "ma20": 253.294,
      "ma50": 247.9872,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 253.014,
      "prevMa50": 247.187,
      "spreadPct": 2.14,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 238.6454,
      "upper": 267.9426,
      "position": "上半部"
    },
    "rsi_short": 78.12,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.95
    }
  }
}

{
  "close": 264.96,
  "volume": 5135400,
  "changePercent": 1.2
}